These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38711520)

  • 1. Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice.
    Jangra S; Lamoot A; Singh G; Laghlali G; Chen Y; Ye T; García-Sastre A; De Geest BG; Schotsaert M
    Front Immunol; 2024; 15():1370564. PubMed ID: 38711520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in QIV vaccinated mice.
    Jangra S; Lamoot A; Singh G; Laghlali G; Chen Y; Yz T; García-Sastre A; De Geest BG; Schotsaert M
    bioRxiv; 2024 Jan; ():. PubMed ID: 38293047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine.
    Jangra S; Laghlali G; Choi A; Rathnasinghe R; Chen Y; Yildiz S; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    Front Immunol; 2022; 13():974016. PubMed ID: 36426358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
    Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders N; Lienenklaus S; David S; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    bioRxiv; 2020 Oct; ():. PubMed ID: 33106810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen.
    Kawai A; Noda M; Hirata H; Munakata L; Matsuda T; Omata D; Takemura N; Onoe S; Hirose M; Kato T; Saitoh T; Hirai T; Suzuki R; Yoshioka Y
    ACS Nano; 2024 Jul; 18(26):16589-16609. PubMed ID: 38885198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.
    Wong PT; Goff PH; Sun RJ; Ruge MJ; Ermler ME; Sebring A; O'Konek JJ; Landers JJ; Janczak KW; Sun W; Baker JR
    Mol Pharm; 2021 Feb; 18(2):679-698. PubMed ID: 32491861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.
    Kulkarni RR; Rasheed MA; Bhaumik SK; Ranjan P; Cao W; Davis C; Marisetti K; Thomas S; Gangappa S; Sambhara S; Murali-Krishna K
    J Virol; 2014 Dec; 88(24):13990-4001. PubMed ID: 25253340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
    Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders NN; Lienenklaus S; David SA; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9467-9473. PubMed ID: 33464672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
    Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C
    Front Immunol; 2021; 12():772550. PubMed ID: 34868036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
    Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
    Front Immunol; 2020; 11():406. PubMed ID: 32210973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.